Vancomycin and the risk of AKI: A systematic review and meta-analysis

Clinical Journal of the American Society of Nephrology

Volumn 11, Issue 12, 2016, Pages 2132-2140

  Ray, Abhisekh Sinha ^a   Haikal, Ammar ^a   Hammoud, Kassem A ^b   Yu, Alan S L ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Acute kidney injury; Acute renal failure; Adult; Clinical epidemiology; Clinical nephrology; Cohort studies; EGFR protein, human; Epidemiology and outcomes; Humans; Incidence; Intelligence; Kidney; Prospective Studies; Receptor, Epidermal Growth Factor; Surveys and Questionnaires

Indexed keywords

CEFTAROLINE; CREATININE; LINEZOLID; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); FOLLOW UP; HUMAN; KIDNEY FUNCTION; META ANALYSIS; NEPHROTOXICITY; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SKIN INFECTION; SOFT TISSUE INFECTION; SYSTEMATIC REVIEW; CHEMICALLY INDUCED; INTRAVENOUS DRUG ADMINISTRATION; PATHOPHYSIOLOGY;

ACUTE KIDNEY INJURY; ADMINISTRATION, INTRAVENOUS; ANTI-BACTERIAL AGENTS; HUMANS; LINEZOLID; RISK FACTORS; VANCOMYCIN;

EID: 85021646661     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05920616     Document Type: Article

References (57)

1. Bailie GR, Neal D: Vancomycin ototoxicity and nephrotoxicity. A review. Med Toxicol 3: 376-386, 1988
2. Cheung RP, DiPiro JT: Vancomycin: An update. Pharmacotherapy 6: 153-169, 1986
3. Nambiar S, Madurawe RD, Zuk SM, Khan SR, Ellison CD, Faustino PJ, Mans DJ, Trehy ML, Hadwiger ME, Boyne MT 2nd, Biswas K, Cox EM: Product quality of parenteral vancomycin products in the United States. Antimicrob Agents Chemother 56: 2819-2823, 2012
4. Nishino Y, Takemura S, Minamiyama Y, Hirohashi K, Ogino T, Inoue M, Okada S, Kinoshita H: Targeting superoxide dismutase to renal proximal tubule cells attenuates vancomycin-induced nephrotoxicity in rats. Free Radic Res 37: 373-379, 2003
5. Wood CA, Kohlhepp SJ, Kohnen PW, Houghton DC, Gilbert DN: Vancomycin enhancement of experimental tobramycin nephrotoxicity. Antimicrob Agents Chemother 30: 20-24, 1986
6. Aronoff GR, Sloan RS, Dinwiddie CB Jr., Glant MD, Fineberg NS, Luft FC: Effects of vancomycin on renal function in rats. Antimicrob Agents Chemother 19: 306-308, 1981
7. Marre R, Schulz E, Anders T, Sack K: Renal tolerance and pharmacokinetics of vancomycin in rats. J Antimicrob Chemother 14: 253-260, 1984
8. Yano Y, Hiraoka A, Oguma T: Enhancement of tobramycin binding to rat renal brush border membrane by vancomycin. J Pharmacol Exp Ther 274: 695-699, 1995
9. Ngeleka M, Beauchamp D, Tardif D, Auclair P, Gourde P, Bergeron MG: Endotoxin increases the nephrotoxic potential of gentamicin and vancomycin plus gentamicin. J Infect Dis 161: 721-727, 1990
10. Eisenberg ES, Robbins N, Lenci M: Vancomycin and interstitial nephritis. Ann Intern Med 95: 658, 1981
11. Bergman MM, Glew RH, Ebert TH: Acute interstitial nephritis associated with vancomycin therapy. Arch Intern Med 148: 2139-2140, 1988
12. Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M: Tubulointerstitial nephritis due to vancomycin. Am J Kidney Dis 14: 512-515, 1989
13. Wai AO, Lo AM, Abdo A, Marra F: Vancomycin-induced acute interstitial nephritis. Ann Pharmacother 32: 1160-1164, 1998
14. Hsu SI: Biopsy-proved acute tubulointerstitial nephritis and toxic epidermal necrolysis associated with vancomycin. Pharmacotherapy 21: 1233-1239, 2001
15. Hong S, Valderrama E, Mattana J, Shah HH, Wagner JD, Esposito M, Singhal PC: Vancomycin-induced acute granulomatous interstitial nephritis: Therapeutic options. Am J Med Sci 334: 296-300, 2007
16. Salazar MN, Matthews M, Posadas A, Ehsan M, Graeber C: Biopsy proven interstitial nephritis following treatment with vancomycin: A case report. Conn Med 74: 139-141, 2010
17. O’Meara P, Borici-Mazi R, Morton AR, Ellis AK: DRESS with delayed onset acute interstitial nephritis and profound refractory eosinophilia secondary to Vancomycin. Allergy Asthma Clin Immunol 7: 16, 2011
18. Htike NL, Santoro J, Gilbert B, Elfenbein IB, Teehan G: Biopsyproven vancomycin-associated interstitial nephritis and acute tubular necrosis. Clin Exp Nephrol 16: 320-324, 2012
19. Wicklow BA, Ogborn MR, Gibson IW, Blydt-Hansen TD: Biopsyproven acute tubular necrosis in a child attributed to vancomycin intoxication. Pediatr Nephrol 21: 1194-1196, 2006
20. Shah-Khan F, Scheetz MH, Ghossein C: Biopsy-proven acute tubular necrosis due to vancomycin toxicity. Int J Nephrol 2011: 436856, 2011
21. Belen C, Budhiraja P, Bracamonte E, Popovtzer M: Biopsy-proven acute tubular necrosis associated with vancomycin in an adult patient. Ren Fail 34: 502-505, 2012
22. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH: A retrospective analysis of possible renal toxicity associated with vancomycin in patientswith health care-associatedmethicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 29: 1107-1115, 2007
23. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL: Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 49: 507-514, 2009
24. Bosso JA, Nappi J, Rudisill C, Wellein M, Bookstaver PB, Swindler J, Mauldin PD: Relationship between vancomycin trough concentrations and nephrotoxicity: A prospective multicenter trial. Antimicrob Agents Chemother 55: 5475-5479, 2011
25. Rostas SE, Kubiak DW, Calderwood MS: High-dose intravenous vancomycin therapy and the risk of nephrotoxicity. Clin Ther 36: 1098-1101, 2014
26. Hanrahan TP, Harlow G, Hutchinson J, Dulhunty JM, Lipman J, Whitehouse T, Roberts JA: Vancomycin-associated nephrotoxicity in the critically ill: A retrospective multivariate regression analysis*. Crit Care Med 42: 2527-2536, 2014
27. Cappelletty D, Jablonski A, Jung R: Risk factors for acute kidney injury in adult patients receiving vancomycin. Clin Drug Investig 34: 189-193, 2014
28. Meaney CJ, Hynicka LM, Tsoukleris MG: Vancomycin-associated nephrotoxicity in adult medicine patients: Incidence, outcomes, and risk factors. Pharmacotherapy 34: 653-661, 2014
29. Liu Y, Yin Y, Liu XZ, Yao HJ, Li LX, Chen JH, Chen T, Lu XT, Bu SH, Zhang J: Retrospective analysis of vancomycin nephrotoxicity in elderly Chinese patients. Pharmacology 95: 279-284, 2015
30. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed January 1, 2016
31. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA; Cochrane Bias Methods Group; Cochrane Statistical Methods Group: The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343: d5928, 2011
32. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 327: 557-560, 2003
33. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schünemann HJ: GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64: 383-394, 2011
34. Rodriguez Colomo O, Álvarez Lerma F, González Pérez MI, Sirvent JM, García Simón M; Study Group of Infection in Critical Patients: Impact of administration of vancomycin or linezolid to critically ill patients with impaired renal function. Eur J Clin Microbiol Infect Dis 30: 635-643, 2011
35. Lodise TP, Lomaestro B, Graves J, Drusano GL: Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 52: 1330-1336, 2008
36. Davies SW, Guidry CA, Petroze RT, Hranjec T, Sawyer RG: Vancomycin and nephrotoxicity: Just another myth? J Trauma Acute Care Surg 75: 830-835, 2013
37. Fujii S, Takahashi S, Makino S, Kunimoto Y, Nakata H, Noda N, Sakurai K, Miyamoto A: Impact of vancomycin or linezolid therapy on development of renal dysfunction and thrombocytopenia in Japanese patients. Chemotherapy 59: 319-324, 2013
38. Chan JD, Pham TN, Wong J, Hessel M, Cuschieri J, Neff M, Dellit TH: Clinical outcomes of linezolid vs vancomycin in methicillinresistant Staphylococcus aureus ventilator-associated pneumonia: Retrospective analysis. J Intensive Care Med 26: 385-391, 2011
39. Peyrani P, Wiemken TL, Kelley R, Zervos MJ, Kett DH, File TM Jr., Stein GE, Ford KD, Scerpella EG, Welch V, Ramirez JA; IMPACTHAP Study Group: Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: Results from the IMPACT-HAP study. Crit Care 18: R118, 2014
40. Kohno S, Yamaguchi K, Aikawa N, Sumiyama Y, Odagiri S, Aoki N, Niki Y, Watanabe S, Furue M, Ito T, Croos-Dabrera R, Tack KJ: Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother 60: 1361-1369, 2007
41. Wilcox MH, Tack KJ, Bouza E, Herr DL, Ruf BR, Ijzerman MM, Croos-Dabrera RV, Kunkel MJ, Knirsch C: Complicated skin and skin-structure infections and catheter-related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clin Infect Dis 48: 203-212, 2009
42. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J: Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: A randomized, controlled study. Clin Infect Dis 54: 621-629, 2012
43. Lin DF, Zhang YY, Wu JF, Wang F, Zheng JC, Miao JZ, Zheng LY, Sheng RY, Zhou X, Shen HH, Ijzerman MM, Croos-Dabrera RV, Sheng W: Linezolid for the treatment of infections caused by Gram-positive pathogens in China. Int J Antimicrob Agents 32: 241-249, 2008
44. Corrado ML: Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 65[Suppl 4]: iv67-iv71, 2010
45. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC Jr., Craig WA, Billeter M, Dalovisio JR, Levine DP: Therapeuticmonitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy 29: 1275-1279, 2009
46. Smith CR, Moore RD, Lietman PS: Studies of risk factors for aminoglycoside nephrotoxicity. Am J Kidney Dis 8: 308-313, 1986
47. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347: 408-415, 2002
48. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE: Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351: 1391-1402, 2004
49. Theravance Biopharma Antibiotics I: Vibativ (Package Insert), 2016. Available at: http://vibativ.com/pdf/PrescribingInformation.pdf. Accessed January 1, 2016
50. Frye RF, Job ML, Dretler RH, Rosenbaum BJ: Teicoplanin nephrotoxicity: First case report. Pharmacotherapy 12: 240-242, 1992
51. Yoshiyama Y, Yazaki T, Kanke M, Beauchamp D: Nephrotoxicity of teicoplanin in rats. Jpn J Antibiot 53: 660-666, 2000
52. Cavalcanti AB, Goncalves AR, Almeida CS, Bugano DD, Silva E: Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev 6: CD007022, 2010
53. Corey GR, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, Giordano P, Lucasti C, Perez A, Good S, Jiang H, Moeck G, O’Riordan W; SOLO I Investigators: Single-dose oritavancin in the treatment of acute bacterial skin infections. NEngl J Med 370: 2180-2190, 2014
54. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW: Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 370: 2169-2179, 2014
55. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH; Linezolid Nosocomial Pneumonia Study Group: Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 25: 980-992, 2003
56. Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ: Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 42: 597-607, 2006
57. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A; Acute Kidney Injury Network: Acute Kidney Injury Network: Report of an initiative to improve outcomes in acute kidney injury. Crit Care 11: R31, 2007